Skip to main navigation

Our Science
AT-527
COVID-19
About Atea
Investors
Careers
Contact

The tip of a pipette pointing towards droplets suspended in a green solution.

Investor Relations

Publications

Breadcrumb

Investors
News & Events
Publications

Publications

Discovery and Preclinical Profiles of Potent Pan-Genotypic Hepatitis E Virus Inhibitors

Source

Conference on Retroviruses and Opportunistic Infections 2026

Read More

Bemnifosbuvir and Ruzasvir Provided as a Fixed-dose Combination Demonstrates High Relative Bioavailability to Their Individual Formulations and Can Be Dosed with No Regard to Food

Source

The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases

Read More

Multiscale Modeling of Results from a Phase 2 Study of an 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Source

The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases

Read More

No Impact of RASs on the High Efficacy of BEM and RZR in Combination: Resistance Analysis from a Phase 2 Study in HCV-Infected Patients

Source

The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases

Read More

Efficacy and Safety of Bemnifosbuvir and Ruzasvir After 8 Weeks of Treatment in Patients With Chronic Hepatitis C Virus (HCV) Infection

Source

European Association for the Study of the Liver (EASL) Congress 2025

Read More

Pharmacokinetics of Bemnifosbuvir in Participants with Hepatic Impairment

Source

European Association for the Study of the Liver (EASL) Congress 2025

Read More

No DDI Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide

Source

European Association for the Study of the Liver (EASL) Congress 2025

Read More

Pharmacokinetics of Bemnifosbuvir in Participants With Renal Impairment

Source

European Association for the Study of the Liver (EASL) Congress 2025

Read More

Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo

Read More

Bemnifosbuvir Poses High Barrier for Resistance in Both Preclinical and Phase 1b Monotherapy Studies

Source

American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2024

Read More

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.

Atea Pharmaceuticals, Inc.
225 Franklin Street
Suite 2100
Boston, MA 02110
(857) 284-8891

Copyright © 2026 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use